Navigation Links
MedImmune Announces Zook as President
Date:11/13/2008

GAITHERSBURG, Md., Nov. 13 /PRNewswire/ -- MedImmune today announced the appointment of Tony Zook as its president. Previously, he had been heading the company on an interim basis.

MedImmune is the wholly owned biologics business for AstraZeneca PLC. In addition to MedImmune, Mr. Zook is also responsible for AstraZeneca's U.S. and Canadian businesses, as well as AstraZeneca's Global Marketing organization.

"I am pleased to continue working with the leadership team here at MedImmune to advance our strategic plan to discover, develop and deliver innovative biologic treatments that can positively impact patient health," stated Tony Zook.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
2. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
3. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
6. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
7. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
8. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
9. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
10. Seneca Valley High School Student Receives Science Award From MedImmune
11. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading producer ... Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 ... form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... for Clinical Ops Executives 2017 in its continued commitment to the advancement of ... makers to discuss current issues related to clinical trial planning and management. ...
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
Breaking Biology Technology:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):